Enerisant HCl

CAS No. 1152749-07-9

Enerisant HCl( —— )

Catalog No. M36346 CAS No. 1152749-07-9

Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 216 In Stock
10MG 347 In Stock
25MG 562 In Stock
50MG 797 In Stock
100MG 1070 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Enerisant HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
  • Description
    Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    P450
  • Recptor
    P450 | Histamine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1152749-07-9
  • Formula Weight
    434.96
  • Molecular Formula
    C22H31ClN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(=O)(C1=CN(N=C1)C2=CC=C(OCCCN3[C@H](C)CCC3)C=C2)N4CCOCC4.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Piperonylic acid

    Piperonylic acid is a natural molecule bearing a methylenedioxy function that closely mimics the structure of trans-cinnamic acid. Piperonylic acid selectively inactivate the CYP73A P450 subpopulation.

  • PF-4981517

    PF-4981517 (CYP3cide) is a efficient, specific and time-dependent inhibitor of cytochrome P4503A4 (CYP3A4). The IC 50 values for CYP3A activity are 0.03 μM,17 μM, and 71 μM for CYP3A4, CYP3A5, and CYP3A7, respectively.

  • Anemosapogenin

    Anemosapogenin shows potent anti-tumor effect in vivo, but it has some toxicity, structure modification should be needed.